The U.S. Food and Drug Administration accepted for review Pfizer Inc.’s Prior Approval Supplement to the Biologics License Application for ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab).
On the cusp of the 2021 American Society of Clinical Oncology meeting, more companies are announcing data presentations that will be made over the four-day conference as BioSpace continues to take a look at some of the data that will be shared.
Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration accepted Mylan’s Biologics License Application (BLA) for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim), for filing through the 351(k) pathway.
